联系客服

600535 沪市 天士力


首页 公告 600535:天士力关于公司2020年半年度主要经营数据的公告

600535:天士力关于公司2020年半年度主要经营数据的公告

公告日期:2020-08-26

600535:天士力关于公司2020年半年度主要经营数据的公告 PDF查看PDF原文

          证券代码:600535        证券简称:天士力        编号:临 2020-075 号

                      天士力医药集团股份有限公司

                关于公司 2020 年半年度主要经营数据的公告

              本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述

          或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。

              根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业信

          息披露指引第七号——医药制造》及《关于做好上市公司 2020 年半年度报告披

          露工作的通知》相关要求,现将公司 2020 年半年度主要经营数据披露如下:

              一、报告期内分行业经营数据

                                                          单位:元币种:人民币

                  主营业务收入                          主营业务成本                  毛利率(%)

行业                                  增长                                  增长  2020  2019  增长
      2020 年 1-6 月  2019 年 1-6 月  率(%) 2020 年 1-6 月  2019 年 1-6 月  率(%) 年 1-6  年 1-6  率
                                                                                      月    月

医药  2,989,342,623.98  3,308,183,343.91  -9.64  825,807,953.52    781,169,586.73    5.71    72.37  76.39  -4.02
工业

医药  5,563,270,726.91  6,069,724,081.66  -8.34  5,042,036,812.36  5,492,491,387.18  -8.20    9.37    9.51  -0.14
商业

合计  8,552,613,350.89  9,377,907,425.57  -8.80  5,867,844,765.88  6,273,660,973.91  -6.47  31.39  33.10  -1.71

                                                          单位:元币种:人民币

      分治疗领域      营业收入        营业成本    毛利率  营业收入比  营业成本比上  毛利率比上

                                                    (%)  上年增减(%) 年增减(%)  年增减(%)

      心脑血管    1,867,507,895.00  506,886,787.71    72.86      -22.58          -6.09        -4.77

        抗肿瘤      380,313,498.89    58,079,273.61    84.73      -14.13        -37.12        5.58

      感冒发烧    220,194,999.83    118,356,904.07    46.25      324.97        377.32        -5.89

      肝病治疗    201,398,477.77    38,841,396.04    80.71      32.70          21.68        1.75

        其他      319,927,752.49    103,643,592.09    67.60      28.26          12.26        4.62


  分治疗领域      营业收入        营业成本    毛利率  营业收入比  营业成本比上  毛利率比上

                                                (%)  上年增减(%) 年增减(%)  年增减(%)

 医药工业小计  2,989,342,623.98  825,807,953.52    72.37      -9.64          5.71        -4.02

 医药商业小计  5,563,270,726.91  5,042,036,812.36    9.37        -8.34          -8.20        -0.14

    合计      8,552,613,350.89  5,867,844,765.88    31.39      -8.80          -6.47        -1.71

                                                      单位:元币种:人民币

  分产品        营业收入        营业成本      毛利率  营业收入比上  营业成本比上  毛利率比上
                                                (%)    年增减(%)  年增减(%)  年增减(%)

  中药      2,085,194,419.67    634,125,337.96    69.59      -12.56          10.38        -6.32

 化学制剂药    793,536,614.66    136,772,005.72    82.76        4.43          -14.37        3.78

 化学原料药    33,200,603.40      18,473,187.63      44.36        23.02          13.35          4.75

  生物药      77,410,986.25      36,437,422.21      52.93      -43.38          18.83        -24.64

医药工业小计  2,989,342,623.98    825,807,953.52    72.37        -9.64          5.71          -4.02

医药商业小计  5,563,270,726.91  5,042,036,812.36    9.37        -8.34          -8.20          -0.14

  合计      8,552,613,350.89  5,867,844,765.88    31.39        -8.80          -6.47          -1.71

          报告期内,公司受到疫情以及三个医保谈判品种执行新价格的影响,除感冒

      发烧药品销售收入较去年同期有大幅增长外,其他大部分产品有不同程度的下

      降。

          公司生物药普佑克 2020 年上半年销量较去年同期增长 30.25%,因执行新的

      医保谈判价格并对渠道库存价格补差导致上半年收入较去年同期下降 43.38%。

          二、报告期内分地区经营数据

                                                      单位:元币种:人民币

            地区        本期累计主营业务收入    上年同期累计主营业务收入  增长比例(%)

          天津市          5,048,507,245.09            5,834,656,425.90          -13.47

          北京市            251,113,208.27              404,883,920.40          -37.98

          广东省            441,083,039.36              540,464,086.63          -18.39

          上海市              77,345,041.09              135,575,725.24          -42.95


    地区        本期累计主营业务收入    上年同期累计主营业务收入  增长比例(%)

  山东省            200,786,479.61              227,346,308.73          -11.68

  山西省            933,149,040.36              814,956,189.13          14.50

  陕西省          2,242,020,371.70            2,370,021,454.86          -5.40

  湖南省            493,315,598.15              595,165,112.88          -17.11

  辽宁省          1,272,602,263.49            1,367,859,824.40          -6.96

  江苏省            668,559,144.20              671,306,089.10          -0.41

    其他              57,159,767.00              103,811,516.65          -44.94

    小计          11,685,641,198.32          13,066,046,653.92          -10.56

    抵消            3,133,027,847.43            3,688,139,228.35          -15.05

    合并            8,552,613,350.89            9,377,907,425.57          -8.80

  注:上表中地区分布以公司所在地划分。

  报告期内,受新冠疫情影响,公司大部分地区的产品销量均有不同程度的下降。上海市销售收入下降 42.95%,主要系普佑克降价所致。

  本公告之经营数据未经审计,提醒投资者审慎使用上述数据。

  特此公告。

                                天士力医药集团股份有限公司董事会

[点击查看PDF原文]